Cargando…

1103 Immunogenicity of 13-valent conjugate pneumococcal vaccine in patients 50 years or older with end stage renal disease on dialysis

Detalles Bibliográficos
Autores principales:	Mitra, Subhashis, Stein, Gary E., Havlichek, Daniel H., Bhupalam, Shyam, Scharmen, Amy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781367/ http://dx.doi.org/10.1093/ofid/ofu052.811

Ejemplares similares

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

1104 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Immunogenicity in the Community Acquired Pneumonia Immunization Trial In Adults (CAPiTA)
por: Van Deursen, Anna M.M., et al.
Publicado: (2014)

1100 Notable Serotype Replacement of Invasive Streptococcus pneumoniae in Kagoshima, Japan, after the Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccines
por: Nishi, Junichiro, et al.
Publicado: (2014)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older
por: Pilishvili, Tamara, et al.
Publicado: (2014)

597 Increase in IPD incidence in Adults in 2013-2014 after 2 consecutive years of decline following introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
por: Baxter, Roger, et al.
Publicado: (2014)

1097 Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Yang, H. Keri, et al.
Publicado: (2014)

1105 Chronic Kidney Disease and Invasive Pneumococcal Disease in Adults
por: Baxter, Roger, et al.
Publicado: (2014)

734 Pneumococcal Bacteremia in Cancer Patients: A Case Series
por: Acevedo, Ileana, et al.
Publicado: (2014)

700 A cohort of pneumococcal bone and joint infections in adult patients
por: Mahieu, Rafael, et al.
Publicado: (2014)

807 Relationship between Respiratory Virus Infection and Pneumococcal Colonization in Children
por: Cho, Eun Young, et al.
Publicado: (2014)

1101 The Gap Widens: Invasive Pneumococcal Serotype Distribution among Adults
por: Grabenstein, John D., et al.
Publicado: (2014)

1677 Macrophage migration inhibitory factor (MIF) promotes clearance of pneumococcal colonization
por: Das, Rituparna, et al.
Publicado: (2014)

1094 Pneumococcal Vaccination Coverage In The Elderly In The United States: Missed Opportunities Continue
por: Yang, H. Keri, et al.
Publicado: (2014)

817 The Association between Asthma and Invasive Pneumococcal Disease: A Nationwide Study in Korea
por: Kwak, Byung Ok
Publicado: (2014)

124 Altered CCL2 Signaling Delays Clearance of Pneumococcal Colonization in Infant Mice
por: Siegel, Steven, et al.
Publicado: (2014)

1095 Invasive Pneumococcal Disease in Children with Underlying Conditions Has Higher Case Fatality and Unique Serotype Distribution
por: Yildirim, Inci, et al.
Publicado: (2014)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

77 Continued Decline in Invasive Pneumococcal Infections in Children Among 8 Children's Hospitals in the United States 2011 to 2013
por: Kaplan, Sheldon L., et al.
Publicado: (2014)

1285 Evaluation of Manual and Automated Bloodstream Infection Surveillance in Outpatient Dialysis Clinics
por: Thompson, Nicola D., et al.
Publicado: (2014)

1669 Genetic Diversity of Pneumolysin and Pneumococcal Histidine Triad Protein D of Streptococcus pneumoniae Isolated from Invasive Infections in Children
por: Yun, Ki Wook, et al.
Publicado: (2014)

1578 Clinical Features, Vaccine Status and S. Pneumoniae Serotypes among HIV-positive and HIV-negative Individuals Diagnosed with Invasive Pneumococcal Disease
por: Muthulingam, Dharushana, et al.
Publicado: (2014)

1146 Prevalence of blood borne viruses in the dialysis unit, Mubarak Al-Kabeer Hospital, Kuwait
por: Altawalah, Haya, et al.
Publicado: (2014)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

1098 The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions
por: Schmoele-Thoma, Beate, et al.
Publicado: (2014)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
por: Bhorat, As’ad E., et al.
Publicado: (2015)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

886 Correlation Between Methods to Calculate Denominators for Dialysis Event Surveillance Using Electronic Health Record Data, Tennessee, 2012
por: Nguyen, Duc, et al.
Publicado: (2014)

1087 Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined DTPa-HBV-IPV/Hib Vaccine in Canadian Aboriginal and non-Aboriginal Infants
por: Scheifele, David W., et al.
Publicado: (2014)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

1080 Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination
por: Block, Stanley L., et al.
Publicado: (2014)

1085 Persistence of Meningococcal Bactericidal Antibodies and Booster Response at 60-Months of Age in Children Who Received Infant Or Toddler Doses of MenACWY-CRM Conjugate Vaccine
por: Klein, Nicola P., et al.
Publicado: (2014)

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
por: Platt, Heather L., et al.
Publicado: (2020)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: An open-label trial
por: Shiramoto, Masanari, et al.
Publicado: (2014)

Evaluation of a 15-valent Pneumococcal Conjugate Vaccine in an Adult Rhesus Macaque Immunogenicity Model
por: Xie, Jinfu, et al.
Publicado: (2017)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f4p8oaep9ucclb8v529v50mv9g